Endometriosis Market
Endometriosis Market Size, Share & Trends Analysis Report by Drug Type (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drug, Progestin, and Oral Contraceptive Pills) by Diagnosis (Ultrasound, Pelvic Exam, Laparoscopy, Magnetic Resonance Imaging (MRI), Hysteroscopy, and Sonohysterography) by Treatment (Hormonal Therapy, and Pain Management), and Low-Power Wide-Area Network (LPWAN)) and by Distribution Channel (Hospital, Drug Stores, Retail Pharmacies, Mail Order Pharmacies, and E-Commerce ) Forecast Period (2025-2035)
Industry Overview
Endometriosis market was valued at $1.8 billion in 2024 and is projected to reach $6.2 billion by 2035, growing at a CAGR of 11.9% during the forecast period (2025–2035). The global endometriosis treatment market is experiencing rapid growth, driven by increasing disease prevalence, rising patient awareness, and advancements in diagnostic and therapeutic technologies, including non-hormonal and minimally invasive options. Key market drivers include greater governmental focus on women's health and funding for research, but challenges persist in the form of high treatment costs, reimbursement hurdles, and the need for more accurate diagnostic tools.
Market Dynamics
Rising Prevalence of Endometriosis and Growing Awareness
The global endometriosis market is primarily driven by the increasing prevalence of the disease among women of reproductive age. Studies indicate that approximately 10% of women worldwide are affected by endometriosis, often leading to chronic pelvic pain, infertility, and reduced quality of life. Growing awareness among women, healthcare providers, and advocacy groups about the symptoms and impact of the condition has led to earlier diagnosis and treatment. Awareness campaigns, educational programs, and social media initiatives have empowered patients to seek medical attention, boosting demand for effective therapies and diagnostic solutions.
Advancements in Diagnostic Techniques
Another key driver supporting market growth is the development and adoption of advanced diagnostic technologies. Traditional methods like pelvic exams and ultrasounds are now supplemented with laparoscopic procedures, magnetic resonance imaging (MRI), hysteroscopy, and sonohysterography, which provide more accurate and early detection of endometriosis. Early diagnosis is critical in managing the disease effectively, reducing complications, and improving patient outcomes. Healthcare providers are increasingly investing in these sophisticated diagnostic tools, which in turn stimulates demand for associated treatments and follow-up care.
Development of Targeted and Hormonal Therapies
Pharmaceutical innovation is a significant driver of the endometriosis market. Companies are focusing on developing targeted therapies and hormonal treatments, including gonadotropin-releasing hormone (GnRH) agonists, progestins, and oral contraceptive pills, that are effective in managing pain, reducing lesion growth, and improving fertility outcomes. New drug formulations offering improved efficacy, reduced side effects, and convenient administration methods, such as oral pills or injectables, are expanding treatment adoption. Additionally, ongoing clinical trials and research into novel therapies are expected to sustain long-term market growth by offering better options for patients who do not respond to conventional treatments.
Market Segmentation
- Based on the drug type, the market is segmented into gonadotropin-releasing hormone agonists, non-steroidal anti-inflammatory drugs, progestins, and oral contraceptive pills.
- Based on the diagnosis, the market is segmented into ultrasound, pelvic exam, laparoscopy, magnetic resonance imaging (MRI), hysteroscopy, and sonohysterography.
- Based on the treatment, the market is segmented into hormonal therapy and pain management.
- Based on the distribution channel, the market is segmented into hospitals, drug stores, retail pharmacies, mail order pharmacies, and e-commerce.
Hormonal Therapy Largest Segment Leading the Global Endometriosis Market
Among all segments in the global endometriosis market, hormonal therapy holds the largest share and is the leading segment. Hormonal therapy includes the use of oral contraceptive pills, progestins, and gonadotropin-releasing hormone (GnRH) agonists, which work by suppressing or regulating hormone levels to reduce the growth of endometrial tissue and alleviate pain. This segment dominates due to its widespread adoption among patients and healthcare providers, proven efficacy, and well-established clinical guidelines supporting its use. Hormonal therapy not only addresses pain management but also helps prevent recurrence after surgical interventions, making it the preferred treatment choice for long-term management of endometriosis.
Laparoscopy: A Key Segment in Market Growth
In terms of diagnosis, laparoscopy remains a significant tool, as it is considered the gold standard for confirming endometriosis. While imaging techniques such as ultrasound and MRI are gaining traction due to their non-invasive nature, laparoscopy remains vital for accurate staging of the disease and guiding treatment decisions. The combination of improved diagnostic techniques and the increasing preference for minimally invasive procedures is enhancing early detection, which in turn stimulates demand for effective drug therapies, such as GnRH agonists.
Regional Outlook
The global endometriosis industry is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Maintains Strong Market Position
North America holds a significant share of the global Endometriosis market. North America, particularly the US, dominates the global endometriosis market, holding a major share in terms of market size and growth. The strong position of the US market can be attributed to several factors, including high healthcare expenditure, advanced medical infrastructure, and widespread awareness about women’s health issues. The presence of well-established pharmaceutical companies, such as AbbVie, Pfizer, and Takeda, actively involved in the research and development of innovative endometriosis therapies, further strengthens the market dominance.
The US benefits from a well-structured healthcare system that supports early diagnosis and effective management of endometriosis. Diagnostic technologies such as laparoscopy, MRI, and ultrasound are widely accessible, enabling the timely identification and treatment of the disease. Additionally, growing awareness campaigns and patient advocacy programs have educated women about the symptoms and long-term impacts of endometriosis, driving early medical intervention and increasing demand for hormonal therapies, GnRH agonists, and other treatment options. Moreover, the regulatory environment in the US is favorable for the introduction of novel therapies. Recent approvals of oral GnRH antagonists and combination hormonal therapies have expanded treatment options, improving patient adherence and outcomes. E-commerce and retail pharmacy networks further facilitate easy access to medications, enhancing market reach.
Market Players Outlook
The major companies operating in the global endometriosis market include AbbVie Inc., AstraZeneca plc, Bayer AG, Pfizer Inc., and Takeda Pharmaceutical Co., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In July 2025, Organon released its Phase 2 ELENA study evaluating the oral HSD17B1 inhibitor OG-6219 for endometriosis-related pain did not meet its primary efficacy endpoint, showing no improvement in pelvic pain compared to placebo. Consequently, the company will discontinue the clinical development program for OG-6219. The double-blind, placebo-controlled study involved pre-menopausal women aged 18 to 49 with moderate-to-severe endometriosis-related pain, assessing efficacy over three treatment cycles using a numerical pain rating scale.
The Report Covers
- Market value data analysis of 2024 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global endometriosis market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Endometriosis Market Sales Analysis – Drug Type | Diagnosis | Treatment | Distribution Channel ($ Million)
- Endometriosis Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Endometriosis Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Global Endometriosis Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Endometriosis Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Endometriosis Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Endometriosis Market Revenue and Share by Manufacturers
- Endometriosis Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- AstraZeneca plc
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Bayer AG
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Takeda Pharmaceutical Company
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- AbbVie Inc.
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Global Endometriosis Market Sales Analysis By Drug Type ($ Million)
- Gonadotropins Releasing Hormone Agonists
- Non-Steroidal Anti-Inflammatory Drug
- Progestin
- Oral Contraceptive Pills
- Global Endometriosis Market Sales Analysis By Diagnosis ($ Million)
- Ultrasound
- Pelvic Exam
- Laparoscopy
- Magnetic Resonance Imaging (MRI)
- Hysteroscopy
- Sonohysterography
- Global Endometriosis Market Sales Analysis By Treatment ($ Million)
- Hormonal Therapy
- Pain Management
- Global Endometriosis Market Sales Analysis By Distribution Channel ($ Million)
- Hospital
- Drug Stores
- Retail Pharmacies
- Mail Order Pharmacies
- E-Commerce
- Regional Analysis
- North American Endometriosis Market Sales Analysis – Drug Type | Diagnosis | Treatment | Distribution Channel ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Endometriosis Market Sales Analysis – Drug Type | Diagnosis | Treatment | Distribution Channel ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Endometriosis Market Sales Analysis – Drug Type | Diagnosis | Treatment | Distribution Channel ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Endometriosis Market Sales Analysis – Drug Type | Diagnosis | Treatment | Distribution Channel ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Astellas Pharma Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Evotec SE
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ferring Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen Pharma
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Myovant Sciences GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Orphagen Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Philogen S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Thermo Fisher Scientific Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Viatris Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zoetis Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Endometriosis Market Research and Analysis By Drug Type, 2024-2035 ($ Million)
2. Global Gonadotropin-Releasing Hormone Agonists For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
3. Global Non-Steroidal Anti-Inflammatory Drug For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
4. Global Progestin For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
5. Global Oral Contraceptive Pills For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
6. Global Endometriosis Market Research and Analysis By Diagnosis, 2024-2035 ($ Million)
7. Global Ultrasound For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
8. Global Pelvic Exam For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
9. Global Laparoscopy For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
10. Global Magnetic Resonance Imaging (MRI) For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
11. Global Hysteroscopy For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
12. Global Sono hysterography For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
13. Global Endometriosis Market Research and Analysis By Treatment, 2024-2035 ($ Million)
14. Global Hormonal Therapy For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
15. Global Pain Management For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
16. Global Endometriosis Market Research and Analysis By Distribution Channel, 2024-2035 ($ Million)
17. Global Hospital For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
18. Global Drug Stores For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
19. Global Retail Pharmacies For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
20. Global Mail Order Pharmacies For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
21. Global E-Commerce For Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
22. Global Endometriosis Market Research and Analysis By Region, 2024-2035 ($ Million)
23. North American Endometriosis Market Research and Analysis By Country, 2024-2035 ($ Million)
24. North American Endometriosis Market Research and Analysis By Drug Type, 2024-2035 ($ Million)
25. North American Endometriosis Market Research and Analysis By Diagnosis, 2024-2035 ($ Million)
26. North American Endometriosis Market Research and Analysis By Treatment, 2024-2035 ($ Million)
27. North American Endometriosis Market Research and Analysis By Distribution Channel Industry, 2024-2035 ($ Million)
28. European Endometriosis Market Research and Analysis By Country, 2024-2035 ($ Million)
29. European Endometriosis Market Research and Analysis By Drug Type, 2024-2035 ($ Million)
30. European Endometriosis Market Research and Analysis By Diagnosis, 2024-2035 ($ Million)
31. European Endometriosis Market Research and Analysis By Treatment, 2024-2035 ($ Million)
32. European Endometriosis Market Research and Analysis By Distribution Channel Industry, 2024-2035 ($ Million)
33. Asia-Pacific Endometriosis Market Research and Analysis By Country, 2024-2035 ($ Million)
34. Asia-Pacific Endometriosis Market Research and Analysis By Drug Type, 2024-2035 ($ Million)
35. Asia-Pacific Endometriosis Market Research and Analysis By Diagnosis, 2024-2035 ($ Million)
36. Asia-Pacific Endometriosis Market Research and Analysis By Treatment, 2024-2035 ($ Million)
37. Asia-Pacific Endometriosis Market Research and Analysis By Distribution Channel Industry, 2024-2035 ($ Million)
38. Rest Of The World Endometriosis Market Research and Analysis By Country, 2024-2035 ($ Million)
39. Rest Of The World Endometriosis Market Research and Analysis By Drug Type, 2024-2035 ($ Million)
40. Rest Of The World Endometriosis Market Research and Analysis By Diagnosis, 2024-2035 ($ Million)
41. Rest Of The World Endometriosis Market Research and Analysis By Treatment, 2024-2035 ($ Million)
42. Rest Of The World Endometriosis Market Research and Analysis By Distribution Channel Industry, 2024-2035 ($ Million)
1. Global Endometriosis Market Share By Drug Type, 2024 Vs 2035 (%)
2. Global Gonadotropin-Releasing Hormone Agonists For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
3. Global Non-Steroidal Anti-Inflammatory Drug For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
4. Global Progestin For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
5. Global Oral Contraceptive Pills For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
6. Global Endometriosis Market Share By Diagnosis, 2024 Vs 2035 (%)
7. Global Ultrasound For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
8. Global Pelvic Exam For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
9. Global Laparoscopy For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
10. Global Magnetic Resonance Imaging (MRI) For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
11. Global Hysteroscopy For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
12. Global Sonohysterography For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
13. Global Endometriosis Market Share By Treatment, 2024 Vs 2035 (%)
14. Global Hormonal Therapy For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
15. Global Pain Management For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
16. Global Endometriosis Market Share By Distribution Channel, 2024 Vs 2035 (%)
17. Global Hospital For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
18. Global Drug Stores For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
19. Global Retail Pharmacies For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
20. Global Mail Order Pharmacies For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
21. Global E-Commerce For Endometriosis Market Share By Region, 2024 Vs 2035 (%)
22. US Endometriosis Market Size, 2024-2035 ($ Million)
23. Canada Endometriosis Market Size, 2024-2035 ($ Million)
24. UK Endometriosis Market Size, 2024-2035 ($ Million)
25. France Endometriosis Market Size, 2024-2035 ($ Million)
26. Germany Endometriosis Market Size, 2024-2035 ($ Million)
27. Italy Endometriosis Market Size, 2024-2035 ($ Million)
28. Spain Endometriosis Market Size, 2024-2035 ($ Million)
29. Russia Endometriosis Market Size, 2024-2035 ($ Million)
30. Rest of Europe Endometriosis Market Size, 2024-2035 ($ Million)
31. India Endometriosis Market Size, 2024-2035 ($ Million)
32. China Endometriosis Market Size, 2024-2035 ($ Million)
33. Japan Endometriosis Market Size, 2024-2035 ($ Million)
34. South Korea Endometriosis Market Size, 2024-2035 ($ Million)
35. Australia and New Zealand Endometriosis Market Size, 2024-2035 ($ Million)
36. ASEAN Economies Endometriosis Market Size, 2024-2035 ($ Million)
37. Rest of Asia-Pacific Endometriosis Market Size, 2024-2035 ($ Million)
38. Latin America Endometriosis Market Size, 2024-2035 ($ Million)
39. Middle East and Africa Endometriosis Market Size, 2024-2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Endometriosis Market in 2024 is estimated to be around $1.8B.
North America holds the largest share in the Endometriosis Market.
Leading players in the Endometriosis Market include AbbVie Inc., AstraZeneca plc, Bayer AG, Pfizer Inc., and Takeda Pharmaceutical Co., among others.
Endometriosis Market is expected to grow at a CAGR of 11.9% from 2025 to 2035.
The growth of the Endometriosis Market is driven by rising prevalence of the disease, increasing awareness among women, and advancements in diagnostic techniques and treatment options.
